Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...
Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)
The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...
WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...
GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...
Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development
China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...
Brii Biosciences Exercises Option for VIR-3434 in Greater China
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...
Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis
China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...
VivaVision Biotech and Dragon Sail Pharmaceutical Partner on Ophthalmology R & D
China’s VivaVision Biotech Inc. has entered into a partnership with compatriot firm Dragon Sail Pharmaceutical....
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...
Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...
Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park
Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...
NHC Releases Technical Guidelines for Drug Clinical Evaluation
The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...
HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...
Hainan Medical Products Administration Issues Guidelines for Imported Drug Management
The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...
Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...